vs
Side-by-side financial comparison of EyePoint, Inc. (EYPT) and Token Cat Ltd (TC). Click either name above to swap in a different company.
EyePoint, Inc. is the larger business by last-quarter revenue ($5.3M vs $2.8M, roughly 1.9× Token Cat Ltd). Token Cat Ltd runs the higher net margin — -3.4% vs -1114.3%, a 1110.9% gap on every dollar of revenue. On growth, Token Cat Ltd posted the faster year-over-year revenue change (-37.9% vs -43.7%).
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
EYPT vs TC — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.3M | $2.8M |
| Net Profit | $-59.4M | $-93.0K |
| Gross Margin | — | 79.0% |
| Operating Margin | -1166.8% | -206.9% |
| Net Margin | -1114.3% | -3.4% |
| Revenue YoY | -43.7% | -37.9% |
| Net Profit YoY | -92.8% | 98.3% |
| EPS (diluted) | $-0.85 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $5.3M | $2.8M | ||
| Q1 25 | $24.5M | — | ||
| Q4 24 | $11.6M | — | ||
| Q3 24 | $10.5M | — | ||
| Q2 24 | $9.5M | $4.4M | ||
| Q1 24 | $11.7M | — | ||
| Q4 23 | $14.0M | — | ||
| Q3 23 | $15.2M | — |
| Q2 25 | $-59.4M | $-93.0K | ||
| Q1 25 | $-45.2M | — | ||
| Q4 24 | $-41.4M | — | ||
| Q3 24 | $-29.4M | — | ||
| Q2 24 | $-30.8M | $-5.6M | ||
| Q1 24 | $-29.3M | — | ||
| Q4 23 | $-14.1M | — | ||
| Q3 23 | $-12.6M | — |
| Q2 25 | — | 79.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 93.0% | — | ||
| Q2 24 | 85.2% | 69.2% | ||
| Q1 24 | 93.5% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | 92.1% | — |
| Q2 25 | -1166.8% | -206.9% | ||
| Q1 25 | -199.7% | — | ||
| Q4 24 | -390.4% | — | ||
| Q3 24 | -311.2% | — | ||
| Q2 24 | -364.5% | -146.9% | ||
| Q1 24 | -285.2% | — | ||
| Q4 23 | -116.6% | — | ||
| Q3 23 | -94.7% | — |
| Q2 25 | -1114.3% | -3.4% | ||
| Q1 25 | -184.8% | — | ||
| Q4 24 | -357.3% | — | ||
| Q3 24 | -279.0% | — | ||
| Q2 24 | -325.3% | -125.9% | ||
| Q1 24 | -250.6% | — | ||
| Q4 23 | -100.5% | — | ||
| Q3 23 | -83.0% | — |
| Q2 25 | $-0.85 | — | ||
| Q1 25 | $-0.65 | — | ||
| Q4 24 | $-0.65 | — | ||
| Q3 24 | $-0.54 | — | ||
| Q2 24 | $-0.58 | — | ||
| Q1 24 | $-0.55 | — | ||
| Q4 23 | $-0.32 | — | ||
| Q3 23 | $-0.33 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $255.7M | $150.0K |
| Total DebtLower is stronger | — | $1.4M |
| Stockholders' EquityBook value | $246.0M | $4.6M |
| Total Assets | $301.1M | $28.4M |
| Debt / EquityLower = less leverage | — | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $255.7M | $150.0K | ||
| Q1 25 | $318.2M | — | ||
| Q4 24 | $370.9M | — | ||
| Q3 24 | $253.8M | — | ||
| Q2 24 | $280.2M | $689.0K | ||
| Q1 24 | $299.3M | — | ||
| Q4 23 | $331.1M | — | ||
| Q3 23 | $136.0M | — |
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q2 25 | $246.0M | $4.6M | ||
| Q1 25 | $298.4M | — | ||
| Q4 24 | $336.5M | — | ||
| Q3 24 | $218.7M | — | ||
| Q2 24 | $228.3M | $-787.0K | ||
| Q1 24 | $249.9M | — | ||
| Q4 23 | $266.3M | — | ||
| Q3 23 | $58.6M | — |
| Q2 25 | $301.1M | $28.4M | ||
| Q1 25 | $362.6M | — | ||
| Q4 24 | $418.5M | — | ||
| Q3 24 | $300.9M | — | ||
| Q2 24 | $324.2M | $12.5M | ||
| Q1 24 | $329.2M | — | ||
| Q4 23 | $355.2M | — | ||
| Q3 23 | $160.0M | — |
| Q2 25 | — | 0.30× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-62.6M | $-23.7M |
| Free Cash FlowOCF − Capex | $-63.8M | — |
| FCF MarginFCF / Revenue | -1196.5% | — |
| Capex IntensityCapex / Revenue | 22.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-194.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-62.6M | $-23.7M | ||
| Q1 25 | $-53.1M | — | ||
| Q4 24 | $-35.8M | — | ||
| Q3 24 | $-39.0M | — | ||
| Q2 24 | $-20.2M | $-1.5M | ||
| Q1 24 | $-31.2M | — | ||
| Q4 23 | $-23.1M | — | ||
| Q3 23 | $-15.2M | — |
| Q2 25 | $-63.8M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $-36.2M | — | ||
| Q3 24 | $-40.6M | — | ||
| Q2 24 | $-21.1M | $-1.5M | ||
| Q1 24 | $-32.4M | — | ||
| Q4 23 | $-24.0M | — | ||
| Q3 23 | $-16.9M | — |
| Q2 25 | -1196.5% | — | ||
| Q1 25 | -218.4% | — | ||
| Q4 24 | -312.7% | — | ||
| Q3 24 | -385.8% | — | ||
| Q2 24 | -222.4% | -34.4% | ||
| Q1 24 | -277.0% | — | ||
| Q4 23 | -171.0% | — | ||
| Q3 23 | -111.3% | — |
| Q2 25 | 22.9% | — | ||
| Q1 25 | 1.1% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 15.0% | — | ||
| Q2 24 | 9.5% | 0.0% | ||
| Q1 24 | 10.2% | — | ||
| Q4 23 | 6.3% | — | ||
| Q3 23 | 11.3% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
